Literature DB >> 32229319

Cannabidiol and tetrahydrocannabinol concentrations in commercially available CBD E-liquids in Switzerland.

Katharina Elisabeth Grafinger1, Severine Krönert1, Alain Broillet1, Wolfgang Weinmann2.   

Abstract

Cannabidiol (CBD) rich hemp and hemp products low in Δ9-tetrahydrocannabinol (THC) (less than 1%) are legally available in Switzerland. Besides herbs for smoking and oils, liquids (e-liquids) for smoking in electronic cigarettes (e-cigs) have recently appeared on the market. These e-liquids are available with different CBD concentrations and can be flavoured. The aim of the current study was to investigate 20 e-liquids legally available in Switzerland for their contents using Fourier-transform infrared spectroscopy (FTIR) as a preliminary step followed by gas-chromatography coupled to mass spectrometry to identify potential cannabinoids, natural plant compounds and flavours. Quantification of CBD, cannabidiol carboxylic acid (CBD-acid), cannabinol (CBN), Δ9-tetrahydrocannabinol (THC), and Δ9-tetrahydrocannabinol carboxylic acid A (THC-acid) was performed by a validated method with ultra-high-pressure-liquid chromatography coupled to a diode array detector (UHPLC-DAD). FTIR analysis could confirm that for all investigated samples the e-liquid matrix consisted of 1,2-propanediol and glycerol. The qualitative GC-MS could identify ten phytocannabinoids including the quantified analytes, six natural plant compounds and five flavours. All analysed samples had a total THC content below 0.1059% (by weight), hence meeting the legal requirements of both Switzerland (<1%) and the European Union (<0.2%). The total CBD content ranged from 0.182 to 3.346% and differed in ten out of 20 samples from the CBD content presented by the manufacturer by more than 10% relative CBD. Furthermore, two of the analysed samples contained only 0.348% and 0.182% total CBD despite being labelled as "CBD rich". Seven of the 20 samples contained the correct CBD content (in the range of the labelled CBD content ± 10%). In conclusion, a deviation in the determined total CBD content from the labelled CBD content could be observed for half of the analysed samples, meaning that consumers cannot rely on the manufacturers' information. It is remarkable, that currently no official regulations for providing correct information of CBD content or any external product control is available in Switzerland and in most other countries.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cannabidiol; E-liquids; Switzerland; Δ(9)-Tetrahydrocannabinol

Year:  2020        PMID: 32229319     DOI: 10.1016/j.forsciint.2020.110261

Source DB:  PubMed          Journal:  Forensic Sci Int        ISSN: 0379-0738            Impact factor:   2.395


  7 in total

1.  Quantification of Cannabis in Infused Consumer Products and Their Residues on Skin.

Authors:  Rosalynn Quiñones; Sara Moreno; Amanda L Smythers; Carrie Sullins; Haley Pijor; Glenna Brown; Ashley Trouten; Lauren L Richards-Waugh; Aladin Siddig
Journal:  ACS Pharmacol Transl Sci       Date:  2022-07-18

Review 2.  Toxicology of flavoring- and cannabis-containing e-liquids used in electronic delivery systems.

Authors:  Aleksandr B Stefaniak; Ryan F LeBouf; Anand C Ranpara; Stephen S Leonard
Journal:  Pharmacol Ther       Date:  2021-03-18       Impact factor: 13.400

3.  CBD, a precursor of THC in e-cigarettes.

Authors:  Zsuzsanna Czégény; Gréta Nagy; Bence Babinszki; Ákos Bajtel; Zoltán Sebestyén; Tivadar Kiss; Boglárka Csupor-Löffler; Barbara Tóth; Dezső Csupor
Journal:  Sci Rep       Date:  2021-04-26       Impact factor: 4.379

4.  Association of Tetrahydrocannabinol Content and Price in Herbal Cannabis Products Offered by Dispensaries in California: A Purview of Consumers/Patients.

Authors:  MaryBeth Dobbins; Mannat Rakkar; Katharine Cunnane; Sarah D Pennypacker; Kimberly G Wagoner; Beth A Reboussin; E Alfonso Romero-Sandoval
Journal:  Front Public Health       Date:  2022-06-17

5.  Impulsivity, Depressive Mood, and Cannabis Use in a Representative Sample of French-Speaking Swiss Young Men.

Authors:  Lucien Rochat; Olivia Mobbs; Joël Billieux; Yasser Khazaal; Christophe Zufferey
Journal:  Psychol Belg       Date:  2022-07-26

6.  Development and Evaluation of Cannabidiol Orodispersible Tablets Using a 23-Factorial Design.

Authors:  Robert-Alexandru Vlad; Paula Antonoaea; Nicoleta Todoran; Emöke-Margit Rédai; Magdalena Bîrsan; Daniela-Lucia Muntean; Silvia Imre; Gabriel Hancu; Lénárd Farczádi; Adriana Ciurba
Journal:  Pharmaceutics       Date:  2022-07-14       Impact factor: 6.525

Review 7.  Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol products.

Authors:  Edward Chesney; Philip McGuire; Tom P Freeman; John Strang; Amir Englund
Journal:  Ther Adv Psychopharmacol       Date:  2020-09-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.